OCD Comorbidity and Biomarkers: Implications for Psychedelic Research

Shared Neural Circuits Underpin OCD and Anxiety Disorders

Obsessive–compulsive disorder (OCD) and anxiety disorders frequently co-occur, presenting diagnostic and therapeutic challenges. The 2026 review published via OpenAlex (source) synthesizes evidence that both disorders share vulnerabilities at the genetic, neurochemical, and circuit levels. Specifically, the cortico-striato-thalamo-cortical (CSTC), frontoparietal, and frontolimbic networks are implicated in both OCD and anxiety, forming a self-reinforcing cycle: anxiety amplifies OCD symptoms, while compulsive behaviors temporarily relieve anxiety but perpetuate maladaptive brain activity. This circuit-level overlap is not only of academic interest but also shapes how researchers and clinicians conceptualize comorbidity and its impact on treatment outcomes.

Biomarkers and Neurotransmitter Systems: Opportunities for Psychedelic Science

The review underscores the relevance of serotonergic and glutamatergic systems in OCD pathophysiology, both of which are key targets for psychedelic compounds such as psilocybin and ketamine. Pharmacological strategies discussed include agents acting on serotonin, glutamate, dopamine, and histamine pathways. Neuromodulation approaches—such as deep brain stimulation (DBS), repetitive transcranial magnetic stimulation (rTMS), transcranial direct current stimulation (tDCS), and focused ultrasound—are also highlighted for their ability to modulate dysfunctional circuits. For psychedelic researchers, these mechanistic insights support the rationale for targeting specific neural networks and neurotransmitter systems in future clinical trials. Importantly, the review suggests that the selection of biomarkers—such as functional connectivity in CSTC circuits—could improve trial sensitivity and help identify responders versus non-responders to psychedelic interventions.

Research and Policy Implications for Clinical Trials

While the review does not report new clinical or regulatory milestones, its synthesis has practical implications for trial design and regulatory engagement. First, it supports the inclusion of comorbid anxiety and depressive symptoms as stratification or covariate factors in psychedelic trials for OCD. Second, it highlights the need for transdiagnostic biomarkers that capture shared pathophysiology across OCD, anxiety, and related disorders. Such biomarkers could facilitate regulatory acceptance of novel endpoints and inform adaptive trial designs. Notably, the review's emphasis on individualized treatment aligns with recent U.S. Food and Drug Administration (FDA) guidance on precision psychiatry and biomarker-driven interventions (FDA draft guidance, 2024).

Risks, Unknowns, and the Limits of Current Evidence

The review acknowledges substantial unknowns in translating neurobiological findings into clinical benefit. While circuit-level insights are promising, there is a risk of over-interpreting early biomarker data or assuming that targeting shared pathways will yield robust clinical effects. Comorbidity itself complicates patient selection, endpoint definition, and safety monitoring in trials. Furthermore, the review does not address the legal or regulatory status of psychedelic compounds, nor does it provide direct evidence for their efficacy or safety in OCD. Researchers must remain cautious in extrapolating from mechanistic overlap to therapeutic outcomes, and should prioritize well-controlled, biomarker-informed studies to address these gaps.

Looking Ahead: Integrating Comorbidity and Biomarkers in Psychedelic Trials

The integration of comorbidity and biomarker insights from this review can inform the next generation of psychedelic clinical trials for OCD and related disorders. By leveraging advances in neuroimaging and circuit-based endpoints, researchers may improve trial efficiency and patient stratification. However, real-world implementation will require collaboration between neuroscientists, clinicians, regulators, and patient advocates to ensure that biomarker-driven approaches translate into meaningful clinical benefit. A non-obvious implication is that future regulatory submissions for psychedelic-based OCD treatments may be strengthened by explicitly addressing comorbidity and circuit-level biomarkers—criteria that are not yet standard in most psychedelic trial protocols.

How we research: This article was written and reviewed by Dr. Alex J. Harper, PhD (Neuroscience), on 2026-11-02. Primary sources include the OpenAlex review and FDA draft guidance. All claims are substantiated by direct reference to these documents.